VANC Pharmaceuticals Inc. Provides Corporate Update – November 1, 2018

VANCOUVER, BC, November 1, 2018 – VANC Pharmaceuticals Inc. (“VANC”) is excited to announce that further to its news release announced October 25, 2018, the Company has received TSX Venture Exchange approval to change its name (the “Name Change”) to Avricore Health Inc. “We are pleased to have received TSX approval for our new name, […]

VANC Contracts with Lampyon to Extend its Corozon Educational and Ecommerce Platform with Medical Cannabis Education and New Sales Capabilities – September 27, 2018

VANCOUVER, BC, September 27, 2018 – VANC Pharmaceuticals Inc. (“VANC”) has contracted with Lampyon Canada Inc. to extend VANC’s proprietary education and ecommerce portal, the Corozon Platform (www.corozonplatform.com), with medical cannabis education and new sales capabilities. Corozon Platform, which is derived from the Latin word for heart, is designed to be the central educational and […]

VANC Pharmaceuticals Retains Investor Relations Firm – August 23, 2018

Vancouver, BC (August 23, 2018) – Vanc Pharmaceuticals Inc. (TSX VENTURE: VANC) ( the “Company”) announced today that it has entered into a consulting agreement with Transcend Capital Inc. (“Transcend”) to develop and implement an investor relations program for the Company. Transcend, with offices in Vancouver, British Columbia, is a full-service investor relations firm that […]

VANC Announces Issuance of Shares for Services Rendered – August 9, 2018

VANCOUVER, BC, August 9, 2018 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”) announces that it has issued a total of 50,458 common shares of the Company to Lampyon Canada Inc., in consideration for services rendered pursuant to the terms of a Service Agreement entered into with VANC on April 10th, 2018. The common shares […]